Drug issues could get some attention as part of a broader agencywide focus on supply chain resilience, but are mostly taking a back seat to other FDA public health initiatives. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
